JPRN-UMIN000002095已完成2 期
Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations (OLCSG0704) - CDDP/DOC(/CPT-11), followed by Gefitinib, GEM/VNB for non-small-cell lung cancer patients
Okayama Lung Cancer Study Group0 个研究点目标入组 30 人开始时间: 2009年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 65years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •Symptomatic brain metastasis, Symptomatic malignant pleural/pericardial effusion Active concomitant malignancy Unstable angina, recent myocardial infarction, heart failure Uncontrolled diabetes or hypertension Pregnant or lactating women Other severe complications
研究者
相似试验
已完成
2 期
ECRIPS: Phase II study of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab with Concurrent Radiotherapy in Patients with local advanced Squamous cell carcinoma of the Head and Neck (LA-SCCHN).JPRN-UMIN000009928CSPOR-HN 01 executive committee55
招募中
2 期
Phase II trial of docetaxel (T), cisplatin (P) and fluorouracil (5-FU) in the treatment of metastatic penile cancerpatients with metastatic penile cancerJPRN-UMIN000002697Fudan University Shanghai Cancer Center40
招募中
2 期
Phase II study of DCS-Tgastric cancerJPRN-jRCTs061180096Takayama Tetsuji30
已完成
2 期
Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)JPRN-UMIN000004368Thoracic Oncology Research Group47
已完成
2 期
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerEsophageal CancerStomach CancerNCT00394433Dana-Farber Cancer Institute38
